Loading, Please Wait...
REDWOOD CITY, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics, announce today that it has appointed Dr. Bahija Jallal, PhD, to its Board of Directors, effective April 17, 2019. The appointment increased the size of Guardant Board of Directors to eight members.
“I am pleased to welcome Bahija to our board of directors. Bahija is a talented leader with deep scientific and operational experience in the immuno-oncology therapeutics space. Her guidance, expertise and deep commitment to patient care will help strengthen Guardant as we advance our mission of conquering cancer with data,” said AmirAli Talazaz, PhD, Guardant Health President and Chairman.
Dr. Jallal has served as the Chief Executive Officer of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that, from October 2013 to January 2019, she served as Executive Vice President of AstraZeneca PLC and President of MedImmune, a subsidiary of AstraZeneca, since January 2013. She joined MedImmune in 2006 and held various research and development positions, including Senior Vice President, Research and Development, from 2010 to 2013.
Dr. Jallal has authored more than 70 peer-reviewed publications and holds more than 15 patents. She has been a member of the boards of directors of Immunocore Limited since January 2019 and of Anthem, Inc. since February 2018. Additionally, she is a member of the of the Board of Trustees of Johns Hopkins University and UMB Health Sciences Research Park Corporation and Past President of the Association for Women in Science.
“I am honored to join the Guardant Board of Directors,” said Dr. Jallal. “Guardant has already made tremendous progress in helping to change how advanced cancer is managed through its platform and I am excited to help them in their mission to greatly improve how cancer is managed and treated throughout all stages of the disease.”
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Lynn Lewis or Carrie Mendivil
Josh Wein or Ian Stone